COMP <GO>
MMED vs UNH // GROSS PROFIT MARGIN
MiniMed Group Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: MMED 3
— UNH 10
▲ GROSS PROFIT MARGIN LEADER: UNH
LAST: $18.90 (+3.39%) • MKT CAP: $5.32B
gross-margins
54.20%
LAST: $400.44 (-1.60%) • MKT CAP: $359.43B
gross-margins
88.31%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MMED VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MMED | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 54.20% | 88.31% | -34.11 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -3.90% | 12.38% | -16.28 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -7.75% | 6.25% | -14.00 | UNH | /fcf-yield <GO> |
| Operating Margin | -6.10% | 5.32% | -11.42 | UNH | /operating-margins <GO> |
| Net Profit Margin | -10.70% | 3.53% | -14.23 | UNH | /net-margins <GO> |
| Revenue Growth (YoY) | 14.30% | 3.33% | +10.97 | MMED | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.29% | -2.29 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.82 | 3.09 | +1.73 | MMED | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | UNH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 7.00% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.4 | 55.1 | -5.70 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.05 | 0.33 | +0.72 | MMED | /macro-sensitivity <GO> |
| Forward P/E Multiple | 24.0x | 17.7x | +6.26 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.32B | $359.43B | -$354.12B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MMED REV | UNH REV | MMED GROSS % | UNH GROSS % | MMED FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.10B | $447.57B | 54.2% | 88.7% | -$420.0M | $16.07B |
| FY 2024 | $2.71B | $400.28B | 56.3% | 88.3% | -$53.0M | $20.70B |
| FY 2023 | $2.47B | $371.62B | — | 89.6% | -$70.1M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MMED // BETA 1.05
UNH // BETA 0.33